Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYS6045 in Advanced HER2-Positive/Expressing/Mutated Solid Tumors
NCT07122063Phase 2Active, not recruiting
- Sponsor
- CSPC Megalith Biopharmaceutical Co., Ltd.
- Start
- Aug 2025
- Primary completion
- Jul 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of SYS6045 in solid tumor (advanced stage), sponsored by CSPC Megalith Biopharmaceutical Co., Ltd. Primary endpoints: Dose-limiting toxicity up to 3 weeks, Adverse Events up to 3 weeks and 2 more. Started Aug 2025; status: active, not recruiting.
02
Drugs
SYS6045
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT07122063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07122063.